Saturday - November 23, 2024
Flagship Pioneering Announces Two New Agreements With Ampersand Biomedicines and Montai Therapeutics Under Its Strategic Partnership With Pfizer
November 21, 2024
CAMBRIDGE, Massachusetts, Nov. 21 -- Flagship Pioneering, a bioplatform innovation company, issued the following news release on Nov. 20, 2024:

* * *

Ampersand's AND Platform will be used to identify programmed biologics for the treatment of obesity-related targets

Montai's CONECTA AI platform will be used to identify small molecules directed to a potential Non-Small Cell Lung Cancer-related target

Collaborations will leverage Pfizer's deep exp . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products